Outcome of childhood B-cell non-Hodgkin lymphoma and B-cell acute lymphoblastic leukemia treated with the Tokyo Children's Cancer Study Group NHL B9604 protocol.
From June 1996 to January 2001, 91 patients with B-cell non-Hodgkin lymphoma or B-cell acute lymphoblastic leukemia up to 18 years of age were enrolled in Tokyo Children's Cancer Study Group (TCCSG) NHL B9604 protocol study. Five-day intensive chemotherapy courses including high-dose methotrexate and high-dose cyclophosphamide were used for localized disease (Groups A and B). High-dose cytarabine was added for advanced disease (Groups C and D). Fifteen patients experienced an adverse event. There were three induction failures, eight relapses (three local, four bone marrow (BM), one BM + local), two toxic deaths and two second malignant neoplasm. Event-free survival at 6 years in Group D and in all patients was 82.4% +/- 9.2% and 81.9% +/- 4.4%, respectively. The TCCSG NHL B9604 protocol achieved an excellent treatment outcome especially in patients with the most advanced disease (Group D: high BM blast cell burden and/or central nervous system involvement).
Kikuchi
Akira
A
Division of Hematology/Oncology, Saitama Children's Medical Center, Saitama-shi Saitama, Japan. a1091069@pref.saitama.lg.jp
Mori
Tetsuya
T
Fujimoto
Jun-Ichiro
J
Kumagai
Masaaki
M
Sunami
Shosuke
S
Okimoto
Yuri
Y
Tsuchida
Masahiro
M
D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use* / Q000633:toxicity; D002051:Burkitt Lymphoma / Q000188:drug therapy* / Q000401:mortality; D002648:Child; D002675:Child, Preschool; D003520:Cyclophosphamide / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D006801:Humans; D007223:Infant; D016393:Lymphoma, B-Cell / Q000188:drug therapy*; D008727:Methotrexate / Q000008:administration & dosage; D016609:Neoplasms, Second Primary; D012008:Recurrence; D016019:Survival Analysis; D016896:Treatment Outcome
D003561:Cytarabine; D003520:Cyclophosphamide; D008727:Methotrexate